



VGX Pharmaceutical Announces Executive Promotions

BLUE BELL, P.A. – July 25, 2006–

VGX Pharmaceuticals announced the promotion of Kevin W. Rassas to Senior Vice President, Business Development and the promotion of Robert Juba Jr. to Senior Director, Manufacturing and Quality.

“Kevin is providing excellent leadership in a variety of areas critical to the development of the Company,” said Dr. Joseph Kim, a CEO and President. “This promotion recognizes his valuable contribution and I am confident that he will continue to play an important role in the overall success of the Company.”

Mr. Rassas joined the Company in 2003 as Vice President. He has over 25 years of pharmaceutical industry experience, including senior level general management responsibility at Searle and Wyeth. He has a strong strategic and operational focus with a proven track record of delivering solid revenue growth and bottom line results. Mr. Rassas has played a major role in the integration of large and complex businesses and has instituted numerous programs to improve operating efficiencies. His background includes significant experience in International Operations P&L Management, Strategic Planning, Business Development, Finance and Administration, New Product Introductions and Joint Ventures. Mr. Rassas received a Bachelor of Arts in Economics from the University of Notre Dame and his MBA in Finance from the Kellogg School of Management at Northwestern University. At VGX, Mr. Rassas has overseen the Company’s overall business development and licensing efforts, including the in-licensing of VGX-1027.

Mr. Juba joined the Company in 2005 as Director. He has been responsible for all of VGX’s global manufacturing activities for its clinical and preclinical programs, including VGX-150, VGX-1027, and VGX-100. Mr. Juba has more than 11 years of experience in the pharmaceutical industry, mostly at Merck & Co. He has managed several contract manufacturing and filling projects for developmental products (Vaccines for Rotavirus and HIV-1), led pilot plant operations for research and clinical supply manufacturing, and provided technical expertise for bacterial vaccine manufacturing. He has extensive experience in managing cGMP processes and operations. Mr. Juba holds both Bachelor's and Master's Degrees in Chemical Engineering from the Massachusetts Institute of Technology.

“Rob provides a wealth of experience in leading a focused effort to advance the Company’s manufacturing planning and capacity not only for our on-going clinical studies but also future clinical projects the Company is planning,” said Dr. Kim.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a leading biopharmaceutical company with strong product candidates for the treatment of infectious diseases including HIV and hepatitis C virus (HCV) as well as cancer and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection and VGX-410C for chronic HCV infection, which are currently in Phase II clinical trials. In addition, a Phase I clinical trial will be initiated in 2006 for the Company's lead cancer drug compound, VGX-150 for the treatment of Melanoma. Moreover, VGX Pharmaceuticals' therapeutic platform is designed to advance a strong and continual pipeline of additional drug candidates into the clinic with VGX-100 for cancer therapy and VGX-1027 and VGX-750 for inflammatory diseases currently in development. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas

Senior Vice President

Tel 267.440.4208

Fax 267.440.4242

E-mail: Rassas@vgxp.com

www.vgxp.com